Lonafarnib, Zoledronic Acid, and Pravastatin ( DrugBank: Pravastatin, Zoledronic acid, Lonafarnib )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 333 | ハッチンソン・ギルフォード症候群 | 1 |
333. ハッチンソン・ギルフォード症候群
臨床試験数 : 8 / 薬物数 : 8 - (DrugBank : 3) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 6
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00916747 (ClinicalTrials.gov) | August 2009 | 5/6/2009 | Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria | An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid Laminopathies | Progeria | Drug: Lonafarnib, Zoledronic Acid, and Pravastatin | Boston Children's Hospital | Schering-Plough;Merck Sharp & Dohme LLC;Eiger BioPharmaceuticals | Active, not recruiting | N/A | N/A | All | 85 | Phase 2 | United States |